Weekly Exenatide Therapy: A Real-World Comparison of Incretin Therapies

Background: Traditional diabetes therapies have been associated with weight gain, hypoglycemia, and/or high secondary failure rates. Glucagon-like peptide-1 (GLP-1) analog use is associated with a minimal risk of hypoglycemia, a persistent average weight loss of 2 to 3 kg, and sustained efficacy eve...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Pharm Technol
Päätekijät: Micale, Sara J., Khatounabadi, Shahabodin, Kane, Michael P., Busch, Robert S., Bakst, Gary, Abelseth, Jill M., Hamilton, Robert A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2014
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5990137/
https://ncbi.nlm.nih.gov/pubmed/34860898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/8755122513518189
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia